Premium
Removal of Lepirudin, a Recombinant Hirudin, by Hemodialysis, Hemofiltration, or Plasmapheresis
Author(s) -
Willey Michelle L.,
Denus Simon,
Spinler Sarah A.
Publication year - 2002
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.22.7.492.33671
Subject(s) - lepirudin , plasmapheresis , medicine , hemodialysis , hirudin , dialysis , hemofiltration , anticoagulant , hemoconcentration , surgery , discovery and development of direct thrombin inhibitors , thrombin , platelet , immunology , antibody , hematocrit
Lepirudin (recombinant hirudin), a direct thrombin inhibitor, is an effective alternative method of anticoagulation in patients with heparin‐induced thrombocytopenia. However, because it is eliminated by the kidneys, the half‐life of lepirudin may be substantially prolonged in patients with renal failure. Patients undergoing hemodialysis must be closely monitored, and therapy must be individualized based on each patient's ability to clear the drug. Current literature on the removal of lepirudin by dialysis or plasmapheresis is limited, but available data suggest that lepirudin can be removed with these methods. The ability of filtration systems to remove lepirudin from the blood is highly dependent on the membrane material used in the system. Understanding the effects of hemodialysis, hemofiltration, and plasmapheresis on lepirudin levels is important, especially since no antidote is available to treat elevated serum lepirudin concentrations.